Jitendra – Page 23 – Scilex Holding

Posts by Jitendra

Home » Articles Posted by Jitendra (Page 23)

28 Dec

Registration of securities – amendment

November 17, 2022
Posted by Jitendra

17 Dec

SEC-generated letter

November 17, 2022
Posted by Jitendra

15 Dec

Registration of Securities

November 17, 2022
Posted by Jitendra

09 Oct

Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released

July 15, 2021
Posted by Jitendra

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020. Title: Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A Conference...

07 Oct

Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020

July 15, 2021
Posted by Jitendra

PALO ALTO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), today announced continuous sales growth in ZTlido® from quarter to quarter in 2020. Scilex expects third quarter 2020...

22 Sep

Characteristics of Analgesic Patch Formulations.

October 6, 2021
Posted by Jitendra

19 Aug

Draft Registration Statement

November 17, 2022
Posted by Jitendra

22 Jun

A Randomized, Open-Label, Bioequivalence Study of Lidocaine Topical System 1.8% and Lidocaine Patch 5% in Healthy Subjects

October 6, 2021
Posted by Jitendra

10 Jun

A Randomized, Crossover, Adhesion Performance and Pharamcokinetic Study of a Lidocaine Topical System Under Conditions of Water Exposure in Healthy Subjects.

October 6, 2021
Posted by Jitendra

02 Jan

Utility of lidocaine as a topical analgesic and improvements in patch delivery systems.

October 1, 2021
Posted by Jitendra

«‹21 222324 25 ›»